Advanced search
1 file | 343.01 KB Add to list

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

(2009) Blood. 113(22). p.5401-5411
Author
Organization
Abstract
Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being life-long, patient adherence is critical. The ADAGIO study aimed to assess prospectively over a 90-day period the prevalence of imatinib nonadherence in CML patients; to develop a multivariate canonical correlation model of how various determinants may be associated with various measures of nonadherence; and to examine whether treatment response is associated with adherence levels. A total of 202 patients were recruited from 34 centers in Belgium, of whom 169 were evaluable. One-third of patients were considered to be nonadherent. Only 14.2% of patients were perfectly adherent with 100% of prescribed imatinib taken. On average, patients with suboptimal response had significantly higher mean percentages of imatinib not taken (23.2%, SD=23.8) than did those with optimal response (7.3%, SD=19.3, P=0.005; percentages calculated as proportions x 100). Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely. It is associated with poorer response to imatinib. Several determinants may serve as alert signals, many of which are clinically modifiable.

Downloads

  • blood-2008-12-196543v1.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 343.01 KB

Citation

Please use this url to cite or link to this publication:

MLA
Noens, Lucien et al. “Prevalence, Determinants, and Outcomes of Nonadherence to Imatinib Therapy in Patients with Chronic Myeloid Leukemia: The ADAGIO Study.” Blood 113.22 (2009): 5401–5411. Print.
APA
Noens, L., Van Lierde, M.-A., De Bock, R., Verhoef, G., Zachée, P., Berneman, Z., Martiat, P., et al. (2009). Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood, 113(22), 5401–5411.
Chicago author-date
Noens, Lucien, Marie-Anne Van Lierde, Robrecht De Bock, Gregor Verhoef, Pierre Zachée, Zwi Berneman, Philippe Martiat, et al. 2009. “Prevalence, Determinants, and Outcomes of Nonadherence to Imatinib Therapy in Patients with Chronic Myeloid Leukemia: The ADAGIO Study.” Blood 113 (22): 5401–5411.
Chicago author-date (all authors)
Noens, Lucien, Marie-Anne Van Lierde, Robrecht De Bock, Gregor Verhoef, Pierre Zachée, Zwi Berneman, Philippe Martiat, Philippe Mineur, Koen Van Eygen, Karen MacDonald, Sabina De Geest, Tara Albrecht, and Ivo Abraham. 2009. “Prevalence, Determinants, and Outcomes of Nonadherence to Imatinib Therapy in Patients with Chronic Myeloid Leukemia: The ADAGIO Study.” Blood 113 (22): 5401–5411.
Vancouver
1.
Noens L, Van Lierde M-A, De Bock R, Verhoef G, Zachée P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401–11.
IEEE
[1]
L. Noens et al., “Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study,” Blood, vol. 113, no. 22, pp. 5401–5411, 2009.
@article{611768,
  abstract     = {Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being life-long, patient adherence is critical. The ADAGIO study aimed to assess prospectively over a 90-day period the prevalence of imatinib nonadherence in CML patients; to develop a multivariate canonical correlation model of how various determinants may be associated with various measures of nonadherence; and to examine whether treatment response is associated with adherence levels. A total of 202 patients were recruited from 34 centers in Belgium, of whom 169 were evaluable. One-third of patients were considered to be nonadherent. Only 14.2% of patients were perfectly adherent with 100% of prescribed imatinib taken. On average, patients with suboptimal response had significantly higher mean percentages of imatinib not taken (23.2%, SD=23.8) than did those with optimal response (7.3%, SD=19.3, P=0.005; percentages calculated as proportions x 100). Nonadherence is more prevalent than patients, physicians, and family members believe it is, and therefore should be assessed routinely. It is associated with poorer response to imatinib. Several determinants may serve as alert signals, many of which are clinically modifiable.},
  author       = {Noens, Lucien and Van Lierde, Marie-Anne and De Bock, Robrecht and Verhoef, Gregor and Zachée, Pierre and Berneman, Zwi and Martiat, Philippe and Mineur, Philippe and Van Eygen, Koen and MacDonald, Karen and De Geest, Sabina and Albrecht, Tara and Abraham, Ivo},
  issn         = {1528-0020},
  journal      = {Blood},
  language     = {eng},
  number       = {22},
  pages        = {5401--5411},
  title        = {Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study},
  url          = {http://dx.doi.org/10.1182/blood-2008-12-196543},
  volume       = {113},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: